Wightman Aaron, Bradford Miranda C, Symons Jordan, Brogan Thomas V
1Division of Nephrology, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI. 2Children's Core for Biomedical Statistics, Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, WA. 3Division of Nephrology, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA. 4Division of Nephrology, Seattle Children's Hospital, Seattle, WA. 5Division of Pediatric Critical Care, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA. 6Division of Critical Care, Seattle Children's Hospital, Seattle, WA.
Pediatr Crit Care Med. 2015 Jul;16(6):576-82. doi: 10.1097/PCC.0000000000000414.
To investigate the prevalence and survival to discharge of neonates with kidney disease who received extracorporeal life support.
We analyzed the Extracorporeal Life Support Organization international registry of neonates (< 30 d old) who received extracorporeal life support from 1989 to 2012. We used International Classification of Diseases and Related Health Problems, 9th Revision, Clinical Modification, codes to identify neonates with kidney disease at time of cannulation for extracorporeal life support.
Participating Extracorporeal Life Support Organization centers.
All neonates who received extracorporeal life support at an Extracorporeal Life Support Organization center from 1989 to 2012.
We performed bivariate logistic regression to estimate associations between survival and covariates. We used unadjusted and adjusted logistic regression to compare survival to discharge between neonates with and without kidney disease. Odds ratios were estimated separately for three groups based on extracorporeal life support indication: pulmonary indication without congenital diaphragmatic hernia, pulmonary indication with congenital diaphragmatic hernia, and cardiac indication. Adjusted models included covariates identified as significant in bivariate models for each group.
The primary outcome measure was survival to discharge from hospitalization. Of the 28,755 neonates who received extracorporeal life support, 405 had kidney disease (extracorporeal life support indication: 210 pulmonary indication without congenital diaphragmatic hernia, 65 pulmonary indication with congenital diaphragmatic hernia, and 130 cardiac indication). Survival was lower in neonates with kidney disease than those without (49% vs 82% pulmonary indication without congenital diaphragmatic hernia, 25% vs 51% pulmonary indication with congenital diaphragmatic hernia, 21% vs 41% cardiac indication). Kidney disease was associated with reduced survival in adjusted models (95% CI for odds ratio 0.31-0.59 pulmonary indication without congenital diaphragmatic hernia, 0.27-0.89 pulmonary indication with congenital diaphragmatic hernia, 0.31-0.77 cardiac indication).
Neonates with kidney disease who receive extracorporeal life support have poorer survival to discharge compared with other neonates who receive extracorporeal life support, suggesting that kidney disease should be considered when making extracorporeal life support initiation decisions.
调查接受体外生命支持的肾病新生儿的患病率及出院存活率。
我们分析了体外生命支持组织国际新生儿登记处(<30日龄)1989年至2012年接受体外生命支持的新生儿数据。我们使用《国际疾病分类及相关健康问题,第九版,临床修订版》编码来识别在进行体外生命支持插管时患有肾病的新生儿。
参与的体外生命支持组织中心。
1989年至2012年在体外生命支持组织中心接受体外生命支持的所有新生儿。
我们进行了双变量逻辑回归分析,以估计存活率与协变量之间的关联。我们使用未调整和调整后的逻辑回归分析,比较患有和未患有肾病的新生儿的出院存活率。根据体外生命支持指征将三组分别估计比值比:无先天性膈疝的肺部指征、有先天性膈疝的肺部指征和心脏指征。调整后的模型包括在每组双变量模型中被确定为显著的协变量。
主要结局指标是出院存活率。在接受体外生命支持的28755例新生儿中,405例患有肾病(体外生命支持指征:210例无先天性膈疝的肺部指征,65例有先天性膈疝的肺部指征,130例心脏指征)。患有肾病的新生儿存活率低于未患肾病的新生儿(无先天性膈疝的肺部指征组中分别为49%和82%,有先天性膈疝的肺部指征组中分别为25%和51%,心脏指征组中分别为21%和41%)。在调整后的模型中,肾病与存活率降低相关(无先天性膈疝的肺部指征组比值比的95%置信区间为0.31 - 0.59,有先天性膈疝的肺部指征组为0.27 - 0.89,心脏指征组为0.31 - 0.77)。
与接受体外生命支持的其他新生儿相比,接受体外生命支持的肾病新生儿出院存活率较低,这表明在做出启动体外生命支持的决策时应考虑肾病因素。